Floatz Rating
CCC49/100
Confidence
Indicative
Sponsor
GELLC (Grupo Español de Leucemia Linfocítica Crónica)
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06926205CT.gov CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL | — | Recruiting | — | — | — |
NCT05672251CT.gov Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Richter Transformation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mosunetuzumab (this asset) | GELLC (Grupo Español de Leucemia Linfocítica Crónica) | P2 | CCC · 49 |
| Obinutuzumab | Christine Ryan | P2 | BB |
| Ibrutinib | City of Hope Medical Center | P2 | BB |
| Venetoclax | Northwestern University | P2 | BB |
| Adriamycin | SWOG Cancer Research Network | P3 | BB |
| Humax-Cd20 | University of Oxford | P2 | BB |
| Cyclophosphamide | SWOG Cancer Research Network | P3 | BB |
| Rituximab | SWOG Cancer Research Network | P3 | BB |
| Pirtobrutinib | SWOG Cancer Research Network | P3 | BB |
+42 more in the Richter Transformation cohort
Other indications for Mosunetuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P3 | BB · 68 |
| Follicular Lymphoma | — | P3 | BB · 65 |
| B-Cell Non-Hodgkin Lymphoma | — | P2 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Mosunetuzumab in Richter Transformation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mosunetuzumab-richter-transformation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →